Oral small-molecule "molecular glue" degrader · newly diagnosed/maintenance multiple myeloma Phase III clinical trial
Official protocol title:A Two-Stage, Randomized, Multicenter, Controlled, Open-Label, Phase III Study Comparing Iberdomide Maintenance Therapy with Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
Trial Summary
This project is a Phase III clinical trial sponsored by Celgene (Bristol Myers Squibb/BMS), primarily targeting patients with newly diagnosed multiple myeloma (NDMM). Eligible patients must have received 3 to 6 cycles of prior induction therapy (including a proteasome inhibitor and an immunomodulatory drug), subsequently completed autologous stem cell transplantation (ASCT), and achieved at least a partial response (PR). Patients are randomized to receive maintenance therapy with either the investigational drug Iberdomide (a novel immunomodulatory agent administered for 21 days of each 28-day cycle) or the control drug lenalidomide (a conventional immunomodulatory agent administered continuously in 28-day cycles) until disease progression or unacceptable toxicity. The trial is conducted concurrently across 38 premier centers in China (including Hong Kong and Taiwan)—such as Peking University People's Hospital, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, The First Affiliated Hospital of Zhejiang University School of Medicine, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, and Qilu Hospital of Shandong University—as well as leading international medical centers across 32 countries, including the United States, the United Kingdom, France, Japan, and Australia.
Participating Centers6 in China + 31 overseas
Source and Verification
Every fact on this page is derived from the original filing below. The source document is archived as a PDF for direct verification.
- Document type
- CDE clinical trial registration filing (original PDF)
- Official registration number
- CTR20232917
- Verify on the NMPA CDE public platformby entering CTR20232917 in the registration-number field. The platform is a search interface with no permanent per-study URL, so a direct link is not possible.
- Last reconciled
- 2026-09-04
Frequently Asked Questions about this Study
Structured facts derived from official protocol filings for patient and family reference
According to official protocol filings (target population synthesized by CMDN from study details, not an official CDE field), this study is primarily designed for patients with [Newly diagnosed/Maintenance]. Eligibility requires verified clinical confirmation by investigators regarding prior lines of therapy, active disease biomarkers, and performance status.
According to verified protocol filings, key eligibility thresholds include: age ≥ 18 years, ECOG performance status ≤ 2. The study specifies 5 inclusion and 6 exclusion criteria covering detailed organ function and medical history. Final enrollment confirmation is determined by investigators at participating hospital trial centers.
The core therapeutic target or investigational mechanism is [Oral small-molecule "molecular glue" degrader (next-generation Cereblon E3 ligase modulator [CELMoD])]. It aims to selectively eradicate clonal plasma cells or redirect anti-tumor immune responses, representing an active area of precision hematology research.
This study is registered as a [Phase III] clinical trial. The protocol is conducted under rigorous ethical and Good Clinical Practice (GCP) oversight approved by institutional ethics committees.
This is an international multi-centre study with 6 study centres in China and 31 overseas centres. The lead institution is [Peking University People's Hospital]. Prominent sites include Peking University People's Hospital, Tongji Medical College of Huazhong University of Science and Technology, Qilu Hospital of Shandong University, among others. Eligible domestic patients can seek screening at the nearest participating centre.
The official public registration identifier for this protocol is [CTR20232917] (CDE_CTR). Patients and researchers can verify registration details and regulatory authorizations directly on the official NMPA CDE platform.
Key Information
Status
Recruiting
Phase
Phase III
Target / Therapy
Oral small-molecule "molecular glue" degrader (next-generation Cereblon E3 ligase modulator [CELMoD])
Sponsor
Bristol-Myers Squibb (China) Investment Co., Ltd.
Principal Investigator
Xiaojun Huang
Lead Institution
Peking University People's Hospital
Participating Centers
6 in China + 31 overseas
CDE Registry ID
CTR20232917
Trial information is translated from the Chinese source record and reviewed by CMDN. Confirm current status and eligibility with the study team.
Where this study sits in the landscape
Browse comparable active studies by disease stage, modality and province
Keywords
Considering a non-trial option?
International participation must be confirmed directly with the study team. If a clinical trial is not practical, review our independent guide to CAR-T in China.
View CAR-T in China Guide →Evidence · Process · Costs · Verified hospitals
Protocol drugs and related tests are fully covered by the sponsor. All studies are strictly supervised by ethics committees, and patients retain the legal right to withdraw at any time.
Read application guide & patient rights